Interested investor may get more information and a copy of the coverage report at: http://acceleronequity.net/ORMP.html
November 3, 2014ORMP announced very favorable top-line results from a Phase 2a trial for its oral insulin capsule in ORMD-0801 for Type 1 diabetes, addressing the multi-billion dollar diabetes market.
- ORMP’s unique Protein Oral Delivery (POD™) technology is a breakthrough in medical science that enables small proteins to travel through the gastrointestinal tract, via the liver, and into the bloodstream to treat a broad number of indications including diabetes.
- POD technology addresses a market of roughly
$50 billionworth of drugs and vaccines that are currently delivered via injections. This includes diabetes, the first indication pursued by OMRP, a market where $20 billionworth insulin was sold globally in 2013.
- The Company’s ORMD-0801 oral insulin capsule has the potential to create a new paradigm in the treatment of Type 2 diabetes by treating the disease at an earlier stage, thereby slowing its progression. Having completed a successful FDA Phase 2a trial in Type 2 diabetes, ORMP is now planning its Phase 2b trial for Type 2 diabetes.
- ORMD-0901, an oral GLP-1 analog, addressing an annual
$2 billionmarket is expected to enter Phase 1b trials in Israelby the end of 2014. In Q3 of 2013 ORMP submitted a Pre-IND package to the U.S. FDA. ORMP expects to begin a Phase II multi-center study for ORMD-0901 in Q3-2015.
Acceleron is a market intelligence service that focuses on identifying and analyzing technically-complicated companies and equities. Acceleron offers a subscription model product to investors and funds with an emphasis in the emerging markets.
Acceleron Equity Research